Ropivacaine

Simpson, Dene; Curran, Monique P; Oldfield, Vicki; Keating, Gillian M.

doi:10.2165/00003495-200565180-00013

Cited by 154 publications

(71 citation statements)

References 208 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When local anaesthesia is used solely, they have a shorter duration of action (6). The duration of analgesia with local anaesthesia alone can be prolonged with the use of indwelling catheters, but misplacement, migration and infection are the inherent problems with catheter placement (7,8). Adjuvants to local anaesthesia provide the benefits of prolonging the duration of action without the need of an additional procedure and risks of catheter insertion (9).…”

Section: Discussionmentioning

confidence: 99%

Comparative Study of the Efficacy of Dexmedetomidine and Fentanyl as Adjuvants to Ropivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Block

Dharmarao

Holyachi

2018

Turk J Anaesth Reanim

View full text Add to dashboard Cite

Objective: Supraclavicular brachial plexus block is preferable to general anaesthesia in upper limb surgeries. Various adjuvants have been added to improve the quality of the block and prolong postoperative analgesia. The aim of the present study was to compare the onset and duration of sensory and motor blockade with the quality of perioperative analgesia and postoperative complications provided by dexmedetomidine and fentanyl as adjuvants to ropivacaine under ultrasound (USG) guidance in supraclavicular block. Methods: A total of 80 patients with American Society of Anesthesiologists grade I/II scheduled for elective upper limb surgeries were randomly allocated into two groups. Group A received 30 mL of 0.5% ropivacaine with 1 µg kg -1 dexmedetomidine, and group B received 30 mL of 0.5% ropivacaine with 1 µg kg -1 fentanyl for supraclavicular brachial block using USG guidance. The onset and duration of sensory and motor block, time for requirement of rescue analgesia and adverse events during the perioperative period were noted. Results: The onset of sensory blockade was 13.95±1.34 min in the dexmedetomidine group and 14.18±1.41 min in the fentanyl group. There was a highly significant statistical difference in terms of the duration of the sensory blockade, i.e. 801.75±46.07 min with dexmedetomidine compared to 590.25±40.41 min with fentanyl (p<0.0001). The duration of motor blockade was highly statistically significant with 649.56±42.73 min in group A compared to 456.75±32.93 min in group B. Conclusion: Dexmedetomidine prolongs the duration of sensory and motor block and postoperative analgesia as compared to fentanyl when used as an adjuvant to ropivacaine in supraclavicular brachial plexus block and is not associated with any major adverse events. Keywords: Ropivacaine, dexmedetomidine, fentanyl, supraclavicular brachial plexus block Amaç: Supraklaviküler brakiyal pleksus bloğu, üst ekstremite ameliyatlarında genel anesteziye tercih edilebilir. Bloğun kalitesini artırmak ve postoperatif analjeziyi uzatmak için çeşitli yardımcı tedaviler eklenmektedir. Bu çalışmanın amacı supraklaviküler blokta utrason eşliğinde ropivakaine yardımcı olarak verilen deksmedetomidin ile fentanili, duyusal ve motor blok başlangıcı ve süresi, perioperatif analjezinin niteliği, ve postoperatif komplikasyonlar açısından karşılaştırmaktır. Yöntemler: ASA (American Society of Anesthesiologists) I/II sını-fında yer alan ve elektif üst ekstremite cerrahisi planlanan toplam 80 hasta rasgele iki gruba bölündü. Ultrason eşliğinde supraklaviküler brakiyal blok için, A grubuna 1 µg kg -1 deksmedetomidin ile birlikte 30 mL %0,5 ropivakain, B grubuna ise 1 µg kg -1 fentanil ile birlikte 30 mL %0.5 ropivakain verildi. Duyusal ve motor bloğun başlangıç ve süreleri, kurtarma analjezi gereksiniminin zamanı, ve perioperatif dönem boyunca yan etkiler kaydedildi. Bulgular: Duyusal bloğun başlaması deksmedetomidin grubunda 13,95±1,34 dakika, fentanil grubunda 14,18±1,41 dk olarak bulundu. Duyusal bloğun süresi açısından istatiksel olarak oldukça anla...

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Study of the Efficacy of Dexmedetomidine and Fentanyl as Adjuvants to Ropivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Block

Dharmarao

Holyachi

2018

Turk J Anaesth Reanim

View full text Add to dashboard Cite

show abstract

“…The relative anesthetic potency ratios are 0.97 (95% CI: 0.81–1.17) for levobupivacaine/bupivacaine, 0.65 (95% CI: 0.54–0.80) for ropivacaine/bupivacaine, and 0.68 (95% CI: 0.55–0.84) for ropivacaine/levobupivacaine 11. Although ropivacaine has lower potency than bupivacaine or levobupivacaine at lower doses (MLAC or ED50), it has similar efficacy to these two agents at clinically relevant doses and concentrations in surgical anesthesia 12,13…”

Section: Pharmacodynamic Propertiesmentioning

confidence: 98%

“…Alpha-1-acid glycoprotein (AAG) is the main binding site for ropivacaine7,12 and binds basic drugs in a low-capacity, high-affinity fashion. The unbound drug concentration is considered to be related to systemic toxicity.…”

Section: Pharmacokinetic Propertiesmentioning

confidence: 99%

Update on the clinical utility and practical use of ropivacaine in Chinese patients

Li¹,

Wan²,

Mei³

et al. 2014

DDDT

View full text Add to dashboard Cite

We reviewed the Chinese and English literature for efficacy and tolerability data as well as pharmacological properties of ropivacaine in Chinese patients. Ropivacaine is a long-acting amide local anesthetic agent that elicits nerve block via reversible inhibition of sodium ion influx in nerve fibers. The available evidence in the literature on anesthesia practice indicates that ropivacaine produces equally surgical sensory block and postoperative and obstetrics analgesia with good maternal and fetal outcome to those of bupivacaine or levobupivacaine. It appears to be associated with comparable onset, quality, and duration of sensory block, but with a lower incidence or grade of motor block, compared to bupivacaine. The satisfaction of both patients and surgeons is high when ropivacaine is used. Thus, ropivacaine appears to be an important option for regional anesthesia and for the management of postoperative and labor pain, with its enhanced sensorimotor differentiation blockage at lower concentrations and enhanced safety at higher concentrations.

show abstract

“…Although RPV is currently state-of-the-art, a major drawback from the formulation point of view is that the application form used in clinic, ropivacaine hydrochloride (Naropin Õ Injection), which should be administered intravenously, is causing poor patient convenience (Simpson et al, 2005). With the improvement of better patient convenience, the needs for smart and innovative preparation forms are accelerating since intravenous infusion is found inconvenient and painful (Segeren et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Preparation and characterization of novel lipid nanocapsules of ropivacaine for transdermal delivery

et al. 2014

View full text Add to dashboard Cite

Ropivacaine, a novel long-acting local anesthetic, has been proved to own superior advantage. However, the application form used in clinic, ropivacaine hydrochloride (Naropin Injection), which should be administed intravenously, is causing poor patient convenience. The purpose of this study was to formulate ropivacaine (RPV) in lipid nanocapsules (LNCs) and character the potential of LNCs in delivering RPV transdermally to exploit novel external preparation. The RPV-LNCs were successfully prepared by phase inversion technique and the formulation was characterized in terms of size, zeta potential, ex vivo permeation study, and pharmacodynamics. The prepared RPV-LNCs displayed a typical core-shell structure with a narrow size distribution of 62.1 ± 1.7 nm and drug loading of 1.35 ± 0.20%. The results of differential scanning calorimetry (DSC) analysis and X-ray diffraction showed that RPV was in amorphous crystalline state when encapsulated into LNCs. Furthermore, the results of ex vivo permeation study displayed that RPV-LNCs had an improved permeability (349.0 ± 11.5 μg cm(-2) versus 161.0 ± 1.3 μg cm(-2)) compared with free RPV. The results of histopathology study showed that interaction between LNCs and skin could break the close conjugation of corneocyte layers. In the mice writhing test, RPV-LNCs exhibited obvious analgesic effect by both prolonging pain latency and reducing the writhing response with an inhibition rate of 91.3% compared to the control group. In conclusion, RPV-LNCs could be a promising delivery system to encapsulate RPV and deliver RPV for transdermal administration.

show abstract

Ropivacaine

Cited by 154 publications

References 208 publications

Comparative Study of the Efficacy of Dexmedetomidine and Fentanyl as Adjuvants to Ropivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Block

Comparative Study of the Efficacy of Dexmedetomidine and Fentanyl as Adjuvants to Ropivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Block

Update on the clinical utility and practical use of ropivacaine in Chinese patients

RETRACTED ARTICLE: Preparation and characterization of novel lipid nanocapsules of ropivacaine for transdermal delivery

Contact Info

Product

Resources

About